Satsuma Pharmaceuticals — Corporate Update (March 2021)
42 slides from Satsuma Pharmaceuticals's corporate update, Mar 1, 2021
Slide 1: Corporate and STS101 (DHE nasal powder for migraine) program update
Corporate and STS101 (DHE nasal powder for migraine) program update Conference call March 1, 2021 NASDAQ: STSA Exhibit 99.2
Slide 2: Important Notice
Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives and expectations for its business operations and financial p
Slide 3: Summary: DHE's anti-migraine effects are differentiated and well-established
DHE’s anti-migraine effects are differentiated and well-established However, route of administration and/or performance of available dosage forms have limited DHE use Summary STS101 (DHE nasal powder) 12/31/20 cash: $68.2M Position & next steps Approved in 1997 Large and growing market with high unm
Slide 4: Presentation overview
Presentation overview EMERGE Phase 3 efficacy trial results Why EMERGE missed on co-primary endpoints and how we can apply what we’ve learned to make our next STS101 Ph3 trial successful STS101 under-delivery Early data entry for co-primary endpoints Very high proportions of subjects and treated att
Slide 5: Phase 3 EMERGE design & enrollment summary
Phase 3 EMERGE design & enrollment summary 28-day electronic headache diary Randomize STS101 5.2 mg DHE STS101 3.9 mg DHE Placebo Confirm patients had ≥ 2 and ≤ 8 migraine attacks during 28-day screening period (consistent with self-reported attack frequency during 3 months prior to initial screenin
Slide 6: Demographics
Demographics 3.9 mg STS101 5.2 mg STS101 Placebo Age (mean) 40.5 40.5 40.1 Gender (% Female) 87.3 87.3 87.4 Race (% White) 81.4 79.6 84.1 Use of preventive medications (%) 15.0 14.4 13.1 Headache Impact Test (HIT-6) score (mean) 64.5 65.5 64.4 HIT-6 score ≥60, indicating severe impact (%) 82.5 88.1
Slide 7: Characteristics of treated attacks
Characteristics of treated attacks (reported at time of treatment) Treated attacks had high rates of characteristics associated with poor treatment outcome Severe symptomology suggests many subjects treated attacks late in the migraine cycle Source:STS101-002 Topline Data September 2020; mITT Popula
Slide 8: STS101 narrowly missed on co-primary efficacy endpoints
STS101 narrowly missed on co-primary efficacy endpoints1 3.9mg 5.2mg Difference vs Placebo 4.7% 4.5% p-value 0.10 0.11 3.9mg 5.2mg Difference vs Placebo 5.4% 6.8% p-value 0.14 0.06 1. Per SAP, any subject with missing data at 2hrs imputed to be nonresponder, irrespective of responder status at the l
Slide 9: Freedom from Pain over time
Freedom from Pain over time Source: STS101-002 Topline Data September 2020; mITT Population * denotes p<0.05 vs placebo * * * * * * * * * STS101 5.2 mg was numerically superior to Placebo at all time points and to STS101 3.9 mg at 9 of 12 time points Difference vs Placebo was significant at 3 hours
Slide 10: Freedom from MBS over time
Freedom from MBS over time Source: STS101-002 Topline Data September 2020; mITT Population Both STS101 dose strengths were significant (p<0.05) versus placebo by 3 hours and through 12 hours * * * * * * * * * * denotes p<0.05 vs placebo Subjects with missing data at a time point imputed as nonrespon
Slide 11: STS101 showed favorable safety & tolerability profile
STS101 showed favorable safety & tolerability profile No Serious Adverse Events No cardiovascular-related Adverse Events No nausea signal Most frequent nasal adverse event (discomfort) occurred in < 6% Adverse Events 3.9 mg STS101 5.2 mg STS101 Placebo Safety Population (n) 363 367 363 At least 1 tr
Slide 12: EMERGE trial summary
EMERGE trial summary High % of treated attacks had characteristics associated with poor treatment outcome Both STS101 dose strengths demonstrated anti-migraine activity, but narrowly missed achieving statistical significance on co-primary endpoints at 2 hours Statistically significant effect by 3 ho
Slide 13: Findings from our EMERGE trial analyses and how we are addressing them
Findings from our EMERGE trial analyses and how we are addressing them Interlinked reasons for EMERGE miss Strategy for addressing in next STS101 Ph3 trial In addition, given safety/tolerability profile observed in EMERGE and to date in ASCEND, a dose strength greater than 5.2 mg should be feasible
Slide 14: STS101 designed for intuitive administration
STS101 designed for intuitive administration – a full dose within seconds Fold Off tab 1 Insert In nostril 2 squeeze to deliver (Repeat 3x) 3
Slide 15: STS101 under-delivery in EMERGE
STS101 under-delivery in EMERGE EMERGE subjects delivered, on average, ~70% of label dose* Reasons: 1. Learning curve effect First use of STS101 (or placebo) by EMERGE subjects was in the treated attack for which efficacy was evaluated Tentativeness with first use → slow pump squeeze 2. STS101 devic
Slide 16: STS101 under-delivery in EMERGE
STS101 under-delivery in EMERGE EMERGE subjects delivered, on average, ~70% of label dose* Reasons: 1. Learning curve effect First use of STS101 (or placebo) by EMERGE subjects was in the treated attack for which efficacy was evaluated Tentativeness with first use → slow pump squeeze 2. STS101 devic
Slide 17: Ensuring adequate delivery of drug in our next STS101 Ph3 trial
Ensuring adequate delivery of drug in our next STS101 Ph3 trial Issues in EMERGE 1. Learning curve effect 2. STS101 devices used in EMERGE Site staff and subject training Subjects practice improved self-administration procedure during screening visits (using STS101 devices filled with inactive powde
Slide 18: Improvements to increase % Emitted Dose
Improvements to increase % Emitted Dose Thinner pump wall for easier squeezing (all STS101 devices in ASCEND) Initial training improvements (ASCEND results don’t reflect full effect of initial training improvements, as implementation initiated several months after study start) Data may reflect some
Slide 19: Findings from our EMERGE trial analyses and how we are addressing them
Findings from our EMERGE trial analyses and how we are addressing them Interlinked reasons for EMERGE miss Strategy for addressing in next STS101 Ph3 trial In addition, given safety/tolerability profile observed in EMERGE and to date in ASCEND, a dose strength greater than 5.2 mg should be feasible
Slide 20: Adjusting time window for eDiary data entry
Adjusting time window and timing of subject prompts for eDiary data entry should increase effect size in our next STS101 Ph3 trial EMERGE 2h nominal time point in eDiary opened for data entry at 1h:45m (with alarm) and closed at 2h:15m Nearly all subjects entered data at or just after 1h:45m Respons
Slide 21: Findings from our EMERGE trial analyses and how we are addressing them
Findings from our EMERGE trial analyses and how we are addressing them Interlinked reasons for EMERGE miss Strategy for addressing in next STS101 Ph3 trial In addition, given safety/tolerability profile observed in EMERGE and to date in ASCEND, a dose strength greater than 5.2 mg should be feasible
Slide 22: Impact of migraine pain intensity in treated attacks
Impact of migraine pain intensity in treated attacks, and how we plan to reduce the proportion of attacks with SEVERE pain intensity Migraine attacks are more difficult to treat when pre-treatment pain intensity has progressed to SEVERE, and baseline pain severity is the key predictor of pain-freedo
Slide 23: Findings from our EMERGE trial analyses and how we are addressing them
Findings from our EMERGE trial analyses and how we are addressing them Interlinked reasons for EMERGE miss Strategy for addressing in next STS101 Ph3 trial In addition, given safety/tolerability profile observed in EMERGE and to date in ASCEND, a dose strength greater than 5.2 mg should be feasible
Slide 24: Minimizing and mitigating placebo response rate in our next STS101 Ph3 trial
Minimizing and mitigating placebo response rate in our next STS101 Ph3 trial Expectation bias Odds of receiving active treatment How investigator & site personnel introduce study & study medication Nasal administration of powder formulation (nose feel) Non-oral treatments that engender sensation (e.
Slide 25: Potential for maximizing efficacy with higher STS101 dose
DHE (mg) Cmax (ng/mL) Time to C ≥ 2.5 ng/mL (minutes) IM/SC DHE 2.9-3.51,5,6 5-151,5,6 STS101 7.8 mg (projected values) 2.67 <157 MAP0004 2.52 102 Sources: 1STS101-001 Data; 2Kellerman et al., J Aerosol Med Pulm Drug Del 2013; 3Winner et al., Headache 1996; 4Aurora et al., Headache 2011; 5Schran et
Slide 26: Potential impact of changes on pain freedom at 2hrs in next Ph3 trial
Potential impact of changes on pain freedom at 2hrs in our next Ph3 trial Estimated Response Rates STS101 Placebo 23-28% 12-15% Values are hypothetical, based on our internal modeling and may not predict clinical trial results In addition, larger sample size of ~700/arm increases power to detect eff
Slide 27: ASCEND open-label, long-term safety trial results to date
ASCEND open-label, long-term safety trial results to date
Slide 28: Preliminary ASCEND results summary
Preliminary ASCEND results summary Last 4 weeks Total to date Attacks treated (by 279 subjects) 639 2,240 % Pain Free @ 2 hrs 37% 30% % Pain Free @ 4 hrs 60% 56% % Pain Free @ 24 hrs 86% 82% % Pain Relief @ 2 hrs 82% 72% Response rates are based on treated attacks for which subjects have reported ef
Slide 29: Preliminary results from ongoing ASCEND study
Preliminary results from ongoing ASCEND study No STS101 related Serious Adverse Events No cardiovascular-related Adverse Events Adverse Events 5.2 mg STS101 Safety Population (n) 283 Most frequent AEs % of subjects reporting AE at least once Dysgeusia 15.1 Nasal discomfort 14.1 Rhinorrhea 7.3 Nasal
Slide 30: Updated STS101 development plan
Updated STS101 development plan
Slide 31: Next steps
Next steps $68.2M cash, equivalents, and marketable securities as of 12/31/2020 Current cash and financing proceeds fund operations into 2H 2023 and through key milestones Anticipated STS101 development milestones Q2 2021 Complete Phase 1 safety and pharmacokinetic study with STS101 5.2 mg and two h
Slide 32: Supplemental slides
Supplemental slides
Slide 33: Some terminology
Some terminology Term Meaning / comment Baseline Time immediately before subject administered study medication 2 hours Post-treatment timepoint when co-primary endpoints were assessed Note: In EMERGE, eDiary prompted subjects to record efficacy beginning at 1h:45m post-treatment and continued to acc
Slide 34: Some dose response trends observed as function of % emitted dose
Some dose response trends observed as function of % emitted dose Higher calculated % emitted dose (ED) generally results in higher response rates across various endpoints 3.5 mg* 1.8 mg* 2.4 mg* 4.6 mg* * calculated mean emitted dose within subgroup 3.9 mg 5.2 mg ≤70% ED >70% ED Placebo ≤70% ED >70%
Slide 35: Pain severity at baseline as key predictor of response at 2 hours
Large body of migraine literature points to pain severity at baseline as the key predictor of response at 2 hours “Treatment and pretreatment pain severity were conclusively the most important predictors of clinical outcome by several orders of magnitude compared with other significant predictors. T
Slide 36: Increasing % of treated attacks with moderate pain at baseline
We can increase % of treated attacks with moderate pain at baseline by utilizing “Historical self-reporting only” screening approach to confirm monthly migraine attacks and headache days Trial Historical self-reporting by subject FOLLOWED BY Prospective validation with eDiary during 28-day screening
Slide 37: Pain Relief@2hr response rate data reported in 9 DHE trials
PD / efficacy measure: Pain Relief@2hr response rate data reported in 9 DHE trials 6 Migranal trials (including 4 trials listed in Migranal label, Boureau & Touchon) 2 MAP0004 trials (Ph2 & Ph3) 1 SC DHE (Winner) PK values Migranal values from STS101-001 Ph1 PK trial MAP0004 values reported by Kelle
Slide 38: STS101 under-delivery consistent with PK/PD model
Actual EMERGE 5.2 mg %PR2h (50.8%) Est. mean Cmax in EMERGE (~1.4 ng/mL) based on observed %ED Projected EMERGE 5.2 mg %PR2h if mean Cmax had been as observed in Ph1 PK trial (~2 ng/mL) PD / efficacy measure: Pain Relief@2hr response rate data reported in 9 DHE trials 6 Migranal trials (including 4
Slide 39: Cmax and early AUC drive DHE efficacy at 2 hrs
Cmax and early AUC drive DHE efficacy at 2 hrs DHE (mg) Cmax (ng/mL) Tmax (minutes) AUC0-30m (ng*hr/mL) % Patients with Pain Relief at 2hrs IM/SC DHE (1 mg) 2.9-3.51,5,6 15-301,5,6 1.31 733 MAP0004 (1 mg) 2.52 102 0.72 594 Sources: 1STS101-001 Data; 2Kellerman et al., J Aerosol Med Pulm Drug Del 201
Slide 40: Placebo response rate in EMERGE was higher than expected
Placebo response rate in EMERGE was higher than expected given the high % of subjects with severe pain at baseline EMERGE actual EMERGE predicted Sources: Diener et al., Neurology 2004; Aurora et al., Headache 2011; Tepper et al., Mayo Clinic Proc 2011; Dodick et al, New Engl J Med 2019; Lipton et a
Slide 41: Pain Freedom at 2h endpoint – sensitivity analysis & modeling
Pain Freedom at 2h endpoint – sensitivity analysis & modeling EMERGE results (5.2 mg STS101) How much any single parameter would need to change to achieve p<0.05 With eDiary data entry shifted from 1:47 to 2:00 EMERGE results (5.2 mg STS101) How much any single parameter would need to change to achi
Slide 42: Powering our next STS101 Ph3 trial and potential outcomes
Powering our next STS101 Ph3 trial and potential outcomes per our modeling EMERGE Next STS101 Ph3 trial Conservative 7.5% effect size Next STS101 Ph3 trial Nominal upside 12.2% effect size Moderate/Severe (%) 49/51 55/45 60/40 N per arm (mITT) ~355 650 650 PF at 2h placebo response rate 14.8% 15.0%
Satsuma Pharmaceuticals — Corporate Update (March 2021) on 6ix